Cardiff Oncology, Inc.
https://cardiffoncology.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cardiff Oncology, Inc.
Cardiff’s Move Into First-Line mCRC Backed By Data From Discontinued Study
Based on advice from the FDA, Cardiff is testing its PLK1 inhibitor onvansertib in first-line metastatic colorectal cancer; data from a discontinued second-line trial may support the hypothesis.
ESMO: Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC
A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.
AACR Round-Up: BMS, Lilly, iTeos, Affimed, Treovir, Revolution And Cardiff
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Trovagene, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice